Novel and efficient method for loading aptamer-conjugated liposomes with arsenic trioxide for targeting cancer cells

References

• Abouaitah, K., et al., 2020. Targeted nano-drug delivery of colchicine against colon cancer cells by means of mesoporous silica nanoparticles. Cancers, 12 (1), 144.
   PubMed Web of Science ®Google Scholar
• Ahn, R.W., et al., 2010. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clinical cancer research, 16 (14), 3607–3617.
   PubMed Web of Science ®Google Scholar
• Akhtar, A., et al., 2017. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. Journal of biomedical research, 31 (3), 177–188.
   PubMed Web of Science ®Google Scholar
• Akhtar, A., et al., 2018. Effective delivery of arsenic trioxide to HPV-positive cervical cancer cells using optimised liposomes: a size and charge study. International journal of molecular sciences, 19 (4), 1081.
   Web of Science ®Google Scholar
• Ali, M.H., Elsherbiny, M.E., and Emara, M., 2019. Updates on aptamer research. International journal of molecular sciences, 20 (10), 2511.
   Web of Science ®Google Scholar
• Alshaer, W., et al., 2015. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjugate chemistry, 26 (7), 1307–1313.
   PubMed Web of Science ®Google Scholar
• Alshaer, W., et al., 2018. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. Journal of controlled release, 271, 98–106.
   PubMed Web of Science ®Google Scholar
• Cadinoiu, A.N., et al., 2019. Aptamer-functionalized liposomes as a potential treatment for basal cell carcinoma. Polymers, 11 (9), 1515.
   PubMed Web of Science ®Google Scholar
• Chen, H., et al., 2006. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. Journal of the American chemical society, 128 (41), 13348–13349.
   PubMed Web of Science ®Google Scholar
• Das, B., et al., 2020. Synthesis and characterization of arsenic(III) oxide nanoparticles as potent inhibitors of MCF 7 cell proliferation through proapoptotic mechanism. BioNanoScience, 10 (2), 420–429.
   Web of Science ®Google Scholar
• Davison, K., Mann, K.K., and Miller, W.H., 2002. Arsenic trioxide: mechanisms of action. Seminars in hematology, 39 (2 Suppl 1), 3–7.
   PubMed Web of Science ®Google Scholar
• Fei, W., et al., 2020. Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: a mini review. International journal of pharmaceutics, 583, 119385.
   PubMed Web of Science ®Google Scholar
• Fei, W., et al., 2017. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. International journal of pharmaceutics, 519 (1–2), 250–262.
   PubMed Web of Science ®Google Scholar
• Fu, X., et al., 2020. Will arsenic trioxide benefit treatment of solid tumor by nano- encapsulation? Mini reviews in medicinal chemistry, 20 (3), 239–251.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2019. Skp2 expression is inhibited by arsenic trioxide through the upregulation of miRNA-330-5p in pancreatic cancer cells. Molecular therapy oncolytics, 12, 214–223.
   PubMed Web of Science ®Google Scholar
• Heydari, M., et al., 2020. Aptamers as potential recognition elements for detection of vitamins and minerals: a systematic and critical review. Critical reviews in clinical laboratory sciences, 57 (2), 126–144.
   PubMed Web of Science ®Google Scholar
• Hoonjan, M., Jadhav, V., and Bhatt, P., 2018. Arsenic trioxide: insights into its evolution to an anticancer agent. Journal of biological inorganic chemistry, 23 (3), 313–329.
   PubMed Web of Science ®Google Scholar
• Huang, W., and Zeng, Y., 2019. A candidate for lung cancer treatment: arsenic trioxide. Clinical & translational oncology, 21 (9), 1115–1126.
   PubMed Web of Science ®Google Scholar
• Jiang, L., Wang, H., and Chen, S., 2020. Aptamer (AS1411)-conjugated liposome for enhanced therapeutic efficacy of miRNA-29b in ovarian cancer. Journal of nanoscience and nanotechnology, 20 (4), 2025–2031.
   PubMed Web of Science ®Google Scholar
• Kallinteri, P., et al., 2004. Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability. Journal of liposome research, 14 (1–2), 27–38.
   PubMed Web of Science ®Google Scholar
• Kong, D., et al., 2020. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Drug delivery, 27 (1), 1729–1740.
   PubMed Web of Science ®Google Scholar
• Li, F., et al., 2017. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature communications, 8 (1), 1390.
   PubMedGoogle Scholar
• Li, Y.M., and Broome, J.D., 1999. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer research, 59 (4), 776–780.
   PubMed Web of Science ®Google Scholar
• Micheletto, Y.M.S., et al., 2015. Investigation of self-association between new glycosurfactant N-acetyl-β-d-glucosaminyl-PEG-docosanate and soybean phosphatidylcholine into vesicles. Colloids and surfaces A: physicochemical and engineering aspects, 467, 166–172.
   Web of Science ®Google Scholar
• Miller, W.H., et al., 2002. Mechanisms of action of arsenic trioxide. Cancer research, 62 (14), 3893–3903.
   PubMed Web of Science ®Google Scholar
• Moosavian, S.A., et al., 2018. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artificial cells, nanomedicine, and biotechnology, 46 (8), 2054–2065.
   PubMed Web of Science ®Google Scholar
• Nogueira, E., et al., 2015. Design of liposomal formulations for cell targeting. Colloids and surfaces. B, biointerfaces, 136, 514–526.
   PubMed Web of Science ®Google Scholar
• Rosenberg, J.E., et al., 2014. A phase II trial of AS1411 a novel nucleolin-targeted DNA aptamer in metastatic renal cell carcinoma. Investigational new drugs, 32 (1), 178–187.
   PubMed Web of Science ®Google Scholar
• Shirani, M., et al., 2020. A novel strategy for detection of small molecules based on aptamer/gold nanoparticles/graphitic carbon nitride nanosheets as fluorescent biosensor. Talanta, 219, 121235.
   PubMed Web of Science ®Google Scholar
• Soundararajan, S., et al., 2008. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer research, 68 (7), 2358–2365.
   PubMed Web of Science ®Google Scholar
• Soundararajan, S., et al., 2009. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Molecular pharmacology, 76 (5), 984–991.
   PubMed Web of Science ®Google Scholar
• Subbarayan, P.R., Lima, M., and Ardalan, B., 2007. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta oncologica, 46 (4), 557–561.
   PubMed Web of Science ®Google Scholar
• Tuerk, C., and Gold, L., 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249 (4968), 505–510.
   PubMed Web of Science ®Google Scholar
• Wang, H.Y., et al., 2019. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Cell death & disease, 10 (6), 1–16.
   Google Scholar
• Wang, X., et al., 2016. Therapeutic potential of delivering arsenic trioxide into HPV-infected cervical cancer cells using liposomal nanotechnology. Nanoscale research letters, 11 (1), 94.
   PubMedGoogle Scholar
• Wu, Q., et al., 2020. Delivery of arsenic trioxide by multifunction nanoparticles to improve the treatment of hepatocellular carcinoma. ACS applied materials & interfaces, 12 (7), 8016–8029.
   PubMed Web of Science ®Google Scholar
• Xie, J., et al., 2017. Design of a novel curcumin-soybean phosphatidylcholine complex-based targeted drug delivery systems. Drug delivery, 24 (1), 707–719.
   PubMed Web of Science ®Google Scholar
• Xu, R., et al., 2019. Bioleaching of realgar nanoparticles using the extremophilic bacterium Acidithiobacillus ferrooxidans DLC-5. Electronic journal of biotechnology, 38, 49–57.
   Web of Science ®Google Scholar
• Yedjou, C., et al., 2010. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. Journal of hematology & oncology, 3 (1), 1–9.
   PubMedGoogle Scholar
• Zhang, T.-D., et al., 2001. Arsenic trioxide, a therapeutic agent for APL. Oncogene, 20 (49), 7146–7153.
   PubMed Web of Science ®Google Scholar
• Zununi Vahed, S., et al., 2019. Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles. Journal of drug targeting, 27 (3), 292–299.
   PubMed Web of Science ®Google Scholar